Lonitab is a prescription medication containing minoxidil, an FDA-approved vasodilator specifically formulated to address androgenetic alopecia in both men and women. It works by prolonging the anagen (growth) phase of the hair follicle, increasing follicular size, and stimulating blood flow to the scalp, which encourages the growth of thicker, stronger hair. This oral treatment offers a systemic approach for patients who have had limited success with topical solutions or require a more convenient administration method. Supported by extensive clinical research, Lonitab represents a significant advancement in the medical management of pattern hair loss, providing a reliable option for dermatologists and patients seeking evidence-based interventions.

Features

• Contains minoxidil as the active pharmaceutical ingredient (API)
• Available in 2.5 mg and 5 mg oral tablet formulations
• Precisely calibrated for consistent systemic delivery
• Manufactured under cGMP (current Good Manufacturing Practices) standards
• Packaged in light-resistant, child-resistant blister packs to ensure stability and safety
• Includes detailed patient information leaflet (PIL) for informed use

Benefits

• Promotes visible hair regrowth in areas affected by pattern baldness
• Increases hair density and shaft diameter for improved coverage
• Offers a convenient, once-daily oral alternative to topical applications
• Supported by robust clinical trial data demonstrating efficacy and safety
• Can be used as monotherapy or in combination with other treatments like finasteride under medical supervision
• Helps improve patient quality of life and self-esteem through restored hair appearance

Common use

Lonitab is primarily indicated for the treatment of androgenetic alopecia (male and female pattern hair loss) in adults. It is prescribed when topical minoxidil has proven ineffective, poorly tolerated, or impractical for the patient. It may also be used off-label, under strict dermatological guidance, for other forms of alopecia such as telogen effluvium or alopecia areata, though evidence for these uses is less established. Treatment is typically long-term, as discontinuation may lead to the reversal of hair growth benefits within several months.

Dosage and direction

The recommended starting dose for men is 5 mg taken orally once daily. For women, the typical dose is 2.5 mg once daily, though some patients may be titrated to 5 mg under medical supervision. Tablets should be swallowed whole with a glass of water, with or without food, though consistency in administration is advised. Dosage adjustments should only be made by a healthcare provider based on therapeutic response and tolerability. Treatment response is typically evaluated after 6–12 months of continuous use.

Precautions

Patients should undergo a thorough cardiovascular assessment before initiation, as minoxidil can cause hypotension and tachycardia. Regular monitoring of blood pressure and heart rate is recommended, especially during the first few weeks of therapy. Use with caution in patients with a history of heart disease, renal impairment, or hypertension. Avoid abrupt discontinuation. Female patients of childbearing potential should use effective contraception during treatment. Not recommended for use in pediatric populations.

Contraindications

Lonitab is contraindicated in patients with hypersensitivity to minoxidil or any excipients in the formulation. It must not be used in individuals with pheochromocytoma, acute myocardial infarction, or severe heart failure. Contraindicated in patients with a history of orthostatic hypotension. Should not be used during pregnancy or breastfeeding due to potential systemic effects on the fetus or infant.

Possible side effects

Common side effects may include hypertrichosis (increased body hair growth), dizziness, headache, fluid retention/edema, and tachycardia. Less frequently, patients may experience dermatological reactions such as rash or itching. Rare but serious adverse effects include pericardial effusion, tamponade, or significant hypotension. Most side effects are dose-dependent and may resolve with dose reduction or discontinuation.

Drug interaction

Lonitab may potentiate the effects of other antihypertensive agents, leading to additive hypotensive effects. Concomitant use with guanethidine may cause severe orthostatic hypotension. Caution is advised when used with drugs that affect cardiac conduction (e.g., beta-blockers, calcium channel blockers). Topical minoxidil should not be used concurrently due to increased risk of systemic absorption and adverse effects.

Missed dose

If a dose is missed, it should be taken as soon as remembered on the same day. If it is nearly time for the next dose, skip the missed dose and resume the regular schedule. Do not double the dose to make up for a missed one. Consistent daily use is important for optimal results.

Overdose

Symptoms of overdose may include severe hypotension, dizziness, tachycardia, fluid retention, and syncope. In case of suspected overdose, seek immediate medical attention. Treatment is supportive and may include intravenous fluids and vasopressors. Hemodialysis is not effective for minoxidil removal.

Storage

Store at room temperature (15–30°C) in a dry place, protected from light and moisture. Keep in the original packaging to maintain stability. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.

Disclaimer

Lonitab is a prescription medication and should be used only under the supervision of a qualified healthcare professional. This information is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Reviews

“After six months on Lonitab 5 mg, I’ve seen a noticeable improvement in my crown coverage. No significant side effects aside from slight initial lightheadedness.” – Mark T., 42

“As a dermatologist, I’ve found Lonitab to be a valuable option for patients who haven’t responded adequately to topical treatments. Monitoring is key.” – Dr. Elena R.

“Effective but the increased body hair was a drawback for me. My doctor adjusted my dose and it became more manageable.” – Sarah L., 36